SeaSpine to Report First Quarter 2021 Financial Results on May 3, 2021

Rhea-AI Summary

SeaSpine Holdings Corporation (NASDAQ: SPNE) will release its first quarter financial results on May 3, 2021, after market close. The management team will host a conference call and webcast at 1:30 PM PT. Interested parties can join the call by dialing (877) 418-4766 domestically or (614) 385-1253 internationally, using Conference ID: 1036925. SeaSpine specializes in surgical solutions for spinal disorders, offering a range of orthobiologics and spinal implants. The company operates in the U.S. and approximately 30 other countries.

Positive

• Scheduled financial results release on May 3, 2021.
• Engagement with investors via conference call.

Negative

• None.

CARLSBAD, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release first quarter financial results after the close of trading on Monday, May 3, 2021. Members of the Company’s management team will host a corresponding conference call and webcast beginning at 1:30 pm PT / 4:30 pm ET.

Individuals interested in listening to the conference call may do so by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, using Conference ID: 1036925. To listen to a live webcast, please visit the Investors section of the SeaSpine website at: www.seaspine.com.

About SeaSpine

SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.

Investor Relations Contact
Leigh Salvo
(415) 937-5402
ir@seaspine.com

FAQ

When will SeaSpine release its first quarter financial results?

SeaSpine will release its first quarter financial results on May 3, 2021.

What time is the SeaSpine conference call?

The SeaSpine conference call is scheduled for 1:30 PM PT on May 3, 2021.

How can I listen to the SeaSpine financial results call?

You can listen to the SeaSpine financial results call by dialing (877) 418-4766 for domestic calls or (614) 385-1253 for international calls.

What is SeaSpine's primary business focus?

SeaSpine focuses on surgical solutions for spinal disorders, providing a range of orthobiologics and spinal implants.

In how many countries does SeaSpine market its products?

SeaSpine markets its products in the U.S. and approximately 30 other countries worldwide.